Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38794
Title: | Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury | Authors: | SPRANGERS, Ben Leaf, David E. Porta, Camillo Soler, Maria Jose Perazella, Mark A. |
Issue Date: | 2022 | Publisher: | NATURE PORTFOLIO | Source: | Nature Reviews Nephrology, 18 (12), p. 794-805 | Abstract: | Immune checkpoint inhibitors are increasingly used as anti-cancer treatments; however, their use can be associated with the development of immune-related adverse events, including acute kidney injury. This Review describes the symptoms, biochemical signs and possible underlying mechanisms of immune checkpoint inhibitor-associated acute kidney injury, and proposes an approach to its diagnosis and management. Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors (ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in oncology continues to grow; however, the increased use of these agents has been associated with a parallel increase in ICI-associated immune-related adverse events, which can affect virtually any organ, including the kidneys. ICI-associated acute kidney injury (ICI-AKI) occurs in 2-5% of patients treated with ICIs. Its occurrence can have important consequences, including the temporary or permanent discontinuation of ICIs or other concomitant anticancer therapies and the need for prolonged treatment with corticosteroids. Various mechanisms have been proposed to underlie the development of ICI-AKI, including loss of tolerance to self-antigens, reactivation of drug-specific effector T cells, and the production of kidney-specific autoantibodies. ICI-AKI most commonly manifests as acute tubulo-interstitial nephritis on kidney biopsy and generally shows a favourable response to early initiation of corticosteroids, with complete or partial remission achieved in most patients. The evaluation of patients with suspected ICI-AKI requires careful diagnostic work-up and kidney biopsy for patients with moderate-to-severe ICI-AKI to ensure accurate diagnosis and inform appropriate treatment. | Notes: | Sprangers, B (corresponding author), Ziekenhuis Oost Limburg, Div Nephrol, Genk, Belgium.; Sprangers, B (corresponding author), UHasselt, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium. Ben.Sprangers@zol.be |
Document URI: | http://hdl.handle.net/1942/38794 | ISSN: | 1759-5061 | e-ISSN: | 1759-507X | DOI: | 10.1038/s41581-022-00630-8 | ISI #: | 000860372800001 | Rights: | Springer Nature Limited 2022 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury.pdf Restricted Access | Published version | 2.15 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.